While oncologists feel comfortable re-challenging patients after grade 1 asymptomatic radiographic pneumonitis resolves—monitoring them closely with six-week CT scans—they refuse to restart trastuzumab deruxtecan following grade 2 ILD. Current clinical literature lacks sufficient safety evidence to justify retreating grade 2 toxicity, leading clinicians to draw a strict line against restarting therapy.
Suspected interstitial lung disease on chest imaging can closely resemble infectious conditions like pneumonia. Involving pulmonary specialists early for inpatient evaluation, viral testing, or bronchoscopy prevents physicians from unnecessarily stopping effective trastuzumab deruxtecan therapy for a misdiagnosed toxicity, while ensuring true pulmonary complications receive rapid steroid or antibiotic intervention.
When sequencing antibody-drug conjugates, switching payloads reduces cross-resistance risk, and emerging evidence shows sequential activity even when targeting the same receptor with distinct payloads. However, clinicians express major concern that sequencing one topoisomerase-1 payload ADC after another could attenuate the second drug's activity, making the initial payload choice critical across gynecologic malignancies.
Faculty consensus establishes chest CT surveillance every nine weeks for patients receiving trastuzumab deruxtecan, narrowing to six-week intervals for higher-risk patients or during ILD re-challenge. For cardiac monitoring, clinicians obtain a baseline echocardiogram followed by repeat evaluations at least every three months to catch asymptomatic declines in left ventricular ejection fraction.
When selecting initial ADC therapy for ovarian cancer patients with dual biomarker expression (FR-alpha positive and HER2-positive), clinicians favor starting with mirvetuximab soravtansine over trastuzumab deruxtecan. Initiating mirvetuximab captures its proven overall survival advantage while keeping trastuzumab deruxtecan available as an effective option for subsequent sequencing.
